Evaluating the clinical effectiveness of new beta-lactam/beta-lactamase inhibitor combination antibiotics: A systematic literature review and meta-analysis
Abstract Background: Ceftazidime/avibactam (C/A), ceftolozane/tazobactam (C/T), imipenem/relebactam (I/R), and meropenem/vaborbactam (M/V) combine either a cephalosporin (C/T and C/A) or a carbapenem antibiotic (M/V and I/R) with a β-lactamase inhibitor. They are used to treat carbapenem-resistant...
Main Authors: | Geneva M. Wilson, Margaret A. Fitzpatrick, Kyle Walding, Beverly Gonzalez, Marin L. Schweizer, Katie J. Suda, Charlesnika T. Evans |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2021-01-01
|
Series: | Antimicrobial Stewardship & Healthcare Epidemiology |
Online Access: | https://www.cambridge.org/core/product/identifier/S2732494X21002175/type/journal_article |
Similar Items
-
beta-lactam synthetase: Implications for beta-lactamase evolution
by: McNaughton, H, et al.
Published: (1998) -
Pseudomonas pseudomallei resistance to beta-lactam antibiotics due to alterations in the chromosomally encoded beta-lactamase.
by: Godfrey, A, et al.
Published: (1991) -
Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
by: François Barbier, et al.
Published: (2023-07-01) -
Hypersensitivity Reactions to Beta-lactam Antibiotics
by: Cansu GÖNCÜOĞLU, et al.
Published: (2021-03-01) -
Carbapenem-sparing beta-lactam/beta-lactamase inhibitors versus carbapenems for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis
by: Huan Zhang, et al.
Published: (2023-03-01)